No ratings yet
Taught by or worked with Georgina? Your rating helps other students choose.
Professor Georgina Long AO is Professor of Melanoma Medical Oncology and Translational Research at the University of Sydney in the Faculty of Medicine and Health. She serves as Medical Director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research at Melanoma Institute Australia and Royal North Shore Hospital. Her academic qualifications include a BSc with first class honours and University Medal, a PhD in Chemistry focused on anti-cancer agents, and an MBBS with honours. She completed a Fulbright Postdoctoral Fellowship at the Scripps Research Institute and became a Fellow of the Royal Australasian College of Physicians in medical oncology in 2008.
Professor Long leads extensive clinical trials and laboratory research at Melanoma Institute Australia, with a primary focus on immuno-oncology and targeted therapies in melanoma, including phase I, II and III trials in neoadjuvant, adjuvant and metastatic settings, as well as studies involving patients with brain metastases. She is chief investigator on NHMRC-funded projects examining the molecular biology of melanoma and biomarkers of therapy response and resistance. She has authored more than 610 peer-reviewed publications in journals including the New England Journal of Medicine, Lancet, Nature and Journal of Clinical Oncology. Her contributions have been recognised with numerous honours, including appointment as an Officer of the Order of Australia in 2020, Australian of the Year in 2024, Fellowship of the Australian Academy of Science in 2024, and Fellowship of the American Society of Clinical Oncology in 2025. Additional awards include the Ramaciotti Medal for Biomedical Research in 2021 and multiple Cancer Institute NSW Premier’s Awards. She has presented at more than 300 international conferences, served as President of the Society for Melanoma Research from 2018 to 2020, and holds roles on scientific committees for ASCO and ESMO as well as editorial boards of high-impact journals. She is a Clarivate highly cited researcher with an h-index of 155.
Discover how University of Sydney's Melanoma Institute Australia's landmark trial demonstrates combination immunotherapy's long-term survival benefits for advanced melanoma, revolutionizing treatment.
Photo by Antoine Dautry on Unsplash
Photo by Chris Liverani on Unsplash
Photo by Peter Burdon on Unsplash
Photo by Andrii Zhuk on Unsplash
Photo by EESOFUFFZICH on Unsplash
Photo by Google DeepMind on Unsplash
Photo by Gabriele Malaspina on Unsplash
.webp){kind=logo}